BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

  Auris Medical Holding Ltd. announced that it has reached the midpoint for enrollment in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.

  May 7, 2019

   · 

  5 min read
• Reuters to make documentary on Paras Biopharmaceuticals Finland Oy - Innovations in Biologics: Insights of a leading expert

  Paras Biopharmaceuticals Finland Oy is proud to announce that Reuters.com / Reuters Plus has selected our Finland-based company, working on biologics manufacturing & innovations in the healthcare segment as a valued contributor to the future of healthcare solutions.

  May 7, 2019

   · 

  2 min read
• Policy

  Evotec SE To Report First Quarter 2019 Results On 14 May 2019

  Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.

  May 7, 2019

   · 

  3 min read
• Deals

  MorphoSys AG Reports First Quarter 2019 Results

  MorphoSys AG reports results for the first quarter of 2019.

  May 7, 2019

   · 

  15 min read
• Apogenix to Present at Four Upcoming International Conferences

  Apogenix announced that it will present updates on its three most advanced HERA-ligands as well as lead drug candidate asunercept at four upcoming international conferences.

  May 7, 2019

   · 

  4 min read
• 

  Drug Development

  PDC*line Pharma obtains authorization to launch phase I/II trial of its cancer vaccine (PDC*lung01) in non-small cell lung cancer

  PDC*line is a potent, scalable and versatile professional antigen-presenting T-cell with great potential for treating a range of cancers

  May 7, 2019

   · 

  5 min read
• 

  Business

  Dr. Christopher J. Schaber’s Interview with The Wall Street Analyzer

  In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the Company with The Wall Street Analyzer.

  May 7, 2019

   · 

  2 min read
• Business

  Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance

  Vericel Corporation reported financial results for the first quarter ended March 31, 2019, and recent business highlights.

  May 7, 2019

   · 

  8 min read
• BioMidwest

  Pantherics Incorporated Awarded STTR Funding from the National Institutes of Health to Advance Asthma Drug Research

  Grant funding will support preclinical studies of a newly discovered medication to control asthma without the use of inhalers

  May 7, 2019

   · 

  3 min read
• Deals

  Retrophin Reports First Quarter 2019 Financial Results

  Retrophin, Inc. reported its first quarter 2019 financial results and provided a corporate update.

  May 7, 2019

   · 

  14 min read